---
questionId: 59
modelId: 妙想
modelDisplayName: 匿名模型F
---

| 药明康德(603259.SH)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2025中报 |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |
| 单季度.营业总收入环比增长率 ![](data:image/png;base64,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)       | 15.43% |
| 单季度.营业总收入同比增长率 ![](data:image/png;base64,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)       | 20.37% |
| 单季度.净利润环比增长率 ![](data:image/png;base64,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)         | 33.09% |
| 单季度.净利润同比增长率 ![](data:image/png;base64,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)         | 113%   |
| 单季度.归属母公司股东的净利润环比增长率 ![](data:image/png;base64,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) | 33.14% |

药明康德2025年第二季度业绩表现强劲，收入和利润均实现显著增长，主要受益于业务扩张和效率提升。以下基于检索到的数据进行分析：

---

**一、收入情况**

1. **营业总收入**  
    2025年第二季度营业总收入为208亿元，同比增长20.37%，环比增长15.43%，显示持续稳健增长趋势。
    
    - 同比增长主要源于化学业务和TIDES业务的强劲表现，其中化学业务收入同比增长33.51%，TIDES业务收入同比增长141.6% 。
    - 环比增长反映业务季节性改善，尤其在临床后期和商业化项目推动下，产能利用率提升。
2. **业务分部表现**
    
    - 化学业务（WuXi Chemistry）收入163.01亿元，同比增长33.51%，毛利率提升至49.07%，主要因小分子CDMO管线扩张和产能优化。
    - 测试业务（WuXi Testing）收入26.89亿元，同比下降1.20%，受市场价格因素影响，但药物安全性评价业务保持亚太领先地位。
    - 生物学业务（WuXi Biology）收入12.52亿元，同比增长7.07%，新分子类型服务贡献超30%收入。

---

**二、利润情况**

1. **净利润**  
    2025年第二季度净利润为85.61亿元，同比增长113%，环比增长33.09%，增速显著高于收入增长。
    
    - 扣除非经常性损益后的净利润为32.53亿元，同比增长36.7%，环比增长39.65%，反映核心业务盈利能力增强。
    - 毛利率为44.45%，同比上升5.1个百分点，主要因生产工艺优化和临床后期项目占比提升。
2. **每股收益**  
    基本每股收益（EPS）为3.01元，同比增长106.16%，环比增长33.14%，受益于净利润增长和流通股减少。
    
    - 净资产收益率（ROE）为13.93%，同比上升6.31个百分点，显示资本回报效率提升。

---

**三、现金流与财务健康**

1. **经营活动现金流**  
    经营活动产生的现金流量净额为74.31亿元，同比增长49.63%，环比改善显著，源于利润增长和运营效率优化。
    
    - 总资产周转率为0.2534次，资产负债率为27.93%，处于稳健水平。
2. **项目进展**
    
    - 小分子D&M管线总数达3,409个，包括76个商业化项目和84个临床III期项目，新增分子412个，推动收入增长。
    - TIDES业务在手订单同比增长48.8%，服务分子数量提升16%，贡献高增长动力。

---

**四、其他关键指标**

1. **业务展望**  
    公司预计2025年持续经营业务收入增速上调至13-17%，全年收入目标上调至425-435亿元，基于在手订单和产能扩张。
    
    - 2025年第二季度新增商业化和临床III期项目8个，强化长期增长基础。
2. **股东回报**  
    公司实施特别分红方案，向全体股东每10股派发现金红利3.50元（含税），已实施完毕。